Abiomed gaining share in Europe with Impella
This article was originally published in Clinica
Executive Summary
Abiomed, which has had a bumpy year with its Impella 2.5 heart pump, has seen its market share grow in Germany and the Netherlands after a recent decision to reimburse the device in the latter. Jefferies analyst Raj Denhoy described the development as “meaningful, considering the opportunity for Impella in Germany and the Netherlands is around 50,000 previously inoperable patients”.